The NIH analytical methods and reference materials program for dietary supplements

被引:35
作者
Betz, Joseph M. [1 ]
Fisher, Kenneth D. [1 ]
Saldanha, Leila G. [1 ]
Coates, Paul M. [1 ]
机构
[1] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA
关键词
bioanalytical methods; natural products; quality assurance; control; reference materials;
D O I
10.1007/s00216-007-1342-8
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Quality of botanical products is a great uncertainty that consumers, clinicians, regulators, and researchers face. Definitions of quality abound, and include specifications for sanitation, adventitious agents (pesticides, metals, weeds), and content of natural chemicals. Because dietary supplements (DS) are often complex mixtures, they pose analytical challenges and method validation may be difficult. In response to product quality concerns and the need for validated and publicly available methods for DS analysis, the US Congress directed the Office of Dietary Supplements (ODS) at the National Institutes of Health (NIH) to accelerate an ongoing methods validation process, and the Dietary Supplements Methods and Reference Materials Program was created. The program was constructed from stakeholder input and incorporates several federal procurement and granting mechanisms in a coordinated and interlocking framework. The framework facilitates validation of analytical methods, analytical standards, and reference materials.
引用
收藏
页码:19 / 25
页数:7
相关论文
共 44 条
[1]
American Herbal Products Association, 2003, Standardization of botanical products: white paper, P33
[2]
Blumenthal M., 2003, ABC CLIN GUIDE HERBS
[3]
The significance of quality for efficacy and safety of herbal medicinal products [J].
Busse, W .
DRUG INFORMATION JOURNAL, 2000, 34 (01) :15-23
[4]
Mechanism of action of St John's wort in depression - What is known? [J].
Butterweck, V .
CNS DRUGS, 2003, 17 (08) :539-562
[5]
*COMM DIET SUPPL L, 1997, REP COMM DIET SUPPL, P17
[6]
Draves Andrew H, 2003, Can J Clin Pharmacol, V10, P114
[7]
Edwards David J, 2003, J Am Pharm Assoc (2003), V43, P419, DOI 10.1331/154434503321831148
[8]
Risks of herbal medicinal products [J].
Ernst, E .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2004, 13 (11) :767-771
[9]
*EUR DIR QUAL MED, 2003, EUR PHARM, P510
[10]
Fenyvesi C., 1998, US NEWS WORLD REP, P70